智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海医药集团青岛国风药业股份有限公司(以下简称“上药国风”)的温经汤颗粒(规格：每袋相当于饮片20g;以下简称“该药品”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的《药品注册证书》(证书编号：2025S01230)，该药品获得批准生产。
温经汤颗粒处方来源于宋•陈自明《妇人大全良方》，并已列入《古代经典名方目录(第一批)》。该药品温经补虚，化瘀止痛。用于血海虚寒，气血凝滞证。症见妇人月经不调，脐腹作痛，脉沉紧。2024年7月上药国风就该药品向国家药监局提出注册上市申请，并获受理。截至本公告日，公司针对该药品已投入研发费用约人民币469万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.